PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31164617-3	2019	The metabolic rates of caffeine, dextromethorphan, midazolam, omeprazole, and Losartan to the CYP-specific metabolites are validated measures of in vivo CYP 1A2, 2D6, 3A4, 2C19, and 2C9 activities, respectively.	Midazolam	51-60	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	153-160	
30762305-0	2019	Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.	Midazolam	165-174	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	49-55	
27127017-9	2016	The primary end points are: in vivo clearance of CYP3A4, CYP2E1 and CYP1A2 substrates, which will be defined by using well-tested probes; midazolam, chlorzoxazone and caffeine.	Midazolam	138-147	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	68-74	
29063606-5	2018	Although CP studies are limited, meta-analysis-based reduction in CYP1A2, CYP2C19, and CYP3A4 enzyme abundances in a virtual oncology population effectively captures CP-PK for caffeine, theophylline, midazolam, simvastatin, omeprazole, and a subset of oncology compounds.	Midazolam	200-209	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	66-72	
25456436-6	2014	RESULT: BER significantly increased the metabolism of midazolam, phenacetin and tolbutamide by inducing the CYP1A2 and 3A4 enzyme in a dose-dependent manner, the mRNA and protein expression of CYP1A2 and 3A4 were increased by berberine at 1000ng mL(-1).	Midazolam	54-63	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	108-114	
25456436-6	2014	RESULT: BER significantly increased the metabolism of midazolam, phenacetin and tolbutamide by inducing the CYP1A2 and 3A4 enzyme in a dose-dependent manner, the mRNA and protein expression of CYP1A2 and 3A4 were increased by berberine at 1000ng mL(-1).	Midazolam	54-63	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	193-199	
25456436-8	2014	CONCLUSION: BER increases the metabolism of cocktail drugs such as midazolam, phenacetin and tolbutamide by increasing the mRNA and protein expression of CYP1A2 and 3A4.	Midazolam	67-76	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	154-160	
24695277-3	2014	Sequential metabolic reactions by Phase I and then Phase II enzymes were found in diclofenac [CYP2C9 and UDP-glucuronyltransferases (UGTs)], midazolam (CYP3A4 and UGTs) and propranolol (CYP1A2/2D6 and UGTs).	Midazolam	141-150	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	186-192	
29403890-2	2014	This method employed a cocktail of six probe substrates (i.e., phenacetin, amodiaquine, diclofenac, S-mephenytoin, dextromethorphan and midazolam for CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4, respectively) as well as individual prototypical inhibitors of the six CYP enzymes in human liver microsomes under optimized incubation conditions.	Midazolam	136-145	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	150-156	
23153057-3	2013	The cocktail strategy (in situ incubation) was used to assess the induction of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 by using the recommended probe substrate, i.e. phenacetin, bupropion, diclofenac and midazolam, respectively.	Midazolam	198-207	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	79-85	
23682612-5	2013	In this study, we investigated the effects of methanol, ethanol, acetonitrile and dimethyl sulfoxide (1% to 4%) on the assessment of km, Vmax and Clint for the metabolism of midazolam via CYP3A4 to 1-hydroxymidazolam and the metabolism of caffeine to paraxanthine via CYP1A2 using expressed enzymes in vitro.	Midazolam	174-183	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	268-274	
22725721-8	2012	RESULTS: The p-PBPK model predicted the PK changes of three model compounds (namely caffeine, metoprolol and midazolam) for CYP1A2, CYP2D6 and CYP3A4 during pregnancy within twofold of observed values.	Midazolam	109-118	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	124-130	
20501911-3	2010	The kinetics of metabolite formation from phenacetin, tolbutamide, and alprazolam and midazolam, selected as substrates probes for CYP1A2, CYP2C9, and CYP3A4, respectively, were characterized in this in vitro system.	Midazolam	86-95	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	131-137	
21885687-1	2012	In this study, the authors developed a phenotyping method for CYP1A2, 2C9, 2C19, 2D6, and 3A4 using a cocktail of 100 mg caffeine, 125 mg tolbutamide, 20 mg omeprazole, 30 mg dextromethorphan, and 2 mg midazolam.	Midazolam	202-211	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	62-68	
22483397-2	2012	CYP isoform specific substrates and their metabolites of CYP1A2 (caffeine), CYP2C9 (losartan), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) and CYP3A (midazolam) were all simultaneously analyzed using LC-MS/MS after administration of a mixture of five drugs (i.e., a "cocktail approach") to healthy volunteers.	Midazolam	154-163	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	57-63	
16049126-4	2005	Phenacetin, diclofenac, S-mephenytoin, bufuralol, and midazolam are used as substrates for CYP1A2, 2C9, 2C19, 2D6, and 3A4, and the assay differentiates between reversible and irreversible inhibition.	Midazolam	54-63	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	91-97	
16857327-7	2006	Correlation analysis between the known CYP enzyme activities and the rates of the formation of 5-hydroxy- and 7-hydroxy-KR-33028 in the 16 human liver microsomes has showed significant correlations with CYP3A4-mediated midazolam 1"-hydroxylation and CYP1A2-mediated phenacetin O-deethylation, respectively.	Midazolam	219-228	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	250-256	
16041547-7	2005	CYP1A2 activity was estimated by calculating the plasma paraxanthine to caffeine AUC ratio (caffeine metabolic ratio; CMR), CYP2C19 activity by the 2-h omeprazole hydroxylation index (HI), CYP2D6 activity by the urinary debrisoquine recovery ratio (DBRR) and CYP3A4 activity by midazolam clearance.	Midazolam	278-287	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-6	
11948533-7	2002	As marker activities, ethoxyresorufin O-deethylation and phenacetin O-deethylation for CYP1A2, bufuralol 1"-hydroxylation and debrisoquin 4-hydroxylation for CYP2D6, testosterone 6beta-hydroxylation and midazolam 1"-hydroxylation for CYP3A4 were compared.	Midazolam	203-212	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	87-93	
10562786-5	1999	Of the seven representative human hepatic P450 isoforms, CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A4, only CYP3A4 catalysed hydroxylation of midazolam, with a K(m) of 3.6 (0.8) mumol liter-1.	Midazolam	138-147	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	57-63	
9867310-3	1998	The main probe drugs include caffeine and theophylline, whose metabolism is catalysed by CYP1A2, tolbutamide, phenytoin and ibuprofen, catalysed by CYP2C9, amitriptyline and nortriptyline, catalysed by CYP2C19, acetaminophen, catalysed by CYP2E1 and lidocaine, midazolam and terfenadine, catalysed by 3A3/4.	Midazolam	261-270	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	89-95	
8423765-11	1993	Verapamil (substrate of CYP3A4 and CYP1A2) and midazolam (substrate of CYP3A4) were competitive inhibitors of N-desalkylpropafenone formation (Ki = 70 microM and 25 microM for verapamil and midazolam, respectively).	Midazolam	190-199	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	35-41